Rheumnow Podcast

Joining the discussion are David Liu, a rheumatologist from Melbourne, and Akhil Sood, a fellow at Stanford with expertise in lupus treatment. They dive into groundbreaking studies from the ACR Annual Meeting, spotlighting promising results for Dapirulizumab in lupus care. The conversation shifts to new therapies and the clinical implications for lupus and advancements in AI for diagnosing inflammatory conditions. They also address the risks of steroid use in rheumatic diseases and the emerging management challenges faced by patients.

ACR 24: What I learned in Sjogren's, Takayasu's and CAR-T:Dr. Janet Pope Anti IL-17 on Entheseal Biopsy in PsA:Dr. Eric Dein  axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure:Dr. Brian Jaros Can We Make Clinical Trials Better?:Dr. Janet Pope Cumulative Steroid Use and Cardiovascular Events:Dr. Mrinalini Dey  IL 6 Inhibitors, Frailty and Polymyalgia Rheumatica:Drs. Trish Harkins and Sebastian Sattui IVIG Treatment in Immune-mediated Necrotizing Myopathy:Drs. Caoilfhionn Connolly interviews Dr. Asim Mohamed  Machine Learning for Predicting Flares in axSpA:Dr. Sheila Reyes So really, are JAKs Safe?:Dr. Janet Pope Tackling the Workforce Crisis: A shared dilemma:Drs. Mrinalini Dey,  Louise Pollard and Bharat Kumar The 2024 ACR Guidelines for Lupus Nephritis:Dr. Sheila Reyes  The Real Value of JAKi is Beyond RA:Dr. David Liew  Vaccine Responses:The DMARD Counts:Dr. David Liew

Joining the discussion are Bella Mehta, a New York rheumatologist specializing in autoimmune diseases, Brian Jaros from Chicago, an expert in giant cell arteritis, and Quilin Conley from Galway, focusing on anti-obesity medications. They delve into new lupus nephritis recommendations and explore the interplay between psoriatic arthritis and immunotherapy mortality risks. Additionally, advancements in predicting vision loss in giant cell arteritis are discussed, alongside the potential of GLP-1 medications to benefit rheumatoid arthritis patients, despite challenges like side effects.

Best Things I Saw Today in PsA:Dr. Catherine Bakewell  Do TNFis and JAKis Prevent Cancer!?:Dr. Richard Conway Efficacy and Safety of Nipocalimab for Sjogren's Syndrome:Dr. Mike Putman Evaluating ANA Patterns and Titers with AI:Dr. Bella Mehta Improvements in Pain and Fatigue in Bimekizumab:Dr. Philip Mease  Long Term Follow up from APIPPRA:Dr. Antoni Chan talks with Dr. Andrew Cope Race Neutral PFTs in Scleroderma Improves Equity:Dr. Caoilfhionn Connolly talks with Dr. Kamini Kuchinad  Summary of JAKi Studies:Dr. Peter Nash The Psoriatic March: PsA before PsO:DR. Antoni Chan Use of AI in Hand Ultrasound Scoring:Dr. Bella Mehta  What is MCTD? The Great Debate:Drs. Caoilfhionn Connolly & Lisa Christopher-Stine What's The State of Biosimilars?:Drs. Eric Dein and Jonathan Kay Pred Softly: Steroids:Dr. Jiha Lee talks with Dr. Beth Wallace

Dr. Philip Mease, a renowned rheumatologist, presents compelling findings on the long-term safety of Bimekizumab for treating axial spondyloarthritis and psoriatic arthritis. Meanwhile, Dr. Eric Dein dives into the nuanced world of rheumatoid arthritis, discussing the critical distinctions between low disease activity and clinical remission. They also explore the implications of statin use alongside JAK inhibitors, shedding light on how these factors affect treatment strategies. Tune in for insights that could reshape RA management!

Delve into the complexities of assessing axial spondyloarthritis with updated measurement techniques. Discover new strategies for managing difficult cases and the surprising prevalence of Diffuse Idiopathic Skeletal Hyperostosis. Explore the exciting yet controversial role of generative AI in rheumatology and its impact on racial disparities in health outcomes. Learn about innovative precision immunotherapy approaches targeting specific T-cell receptors in ankylosing spondylitis. Lastly, uncover the latest steroid-sparing strategies for treating Giant Cell Arteritis and Polymyalgia Rheumatica.

Dr. Andrea Fava, a researcher specializing in autoimmune diseases, discusses groundbreaking research on fibroblasts and their role in conditions like lupus. She introduces an innovative urinary biomarker that could revolutionize lupus nephritis diagnosis. The podcast also highlights legislative efforts for better healthcare access and underscores the importance of monitoring cardiovascular health in autoimmune patients. Additionally, discussions touch on gender differences in disease management, advocating for tailored approaches to improve patient outcomes.

Rinaldi Day, a clinical fellow from London, and Eric Dian, a rheumatologist from Summit, New Jersey, dive into the cutting-edge insights from the ACR Annual Meeting. They discuss a pivotal study linking steroid use to cardiovascular events in rheumatoid arthritis and share findings on optimizing treatment for giant cell arteritis. The conversation touches on racial biases in lung function calculations and the disparities in medication outcomes for connective tissue diseases, highlighting the urgent need for improved management strategies and monitoring.

Joining the discussion are Peter Nash, an expert on JAK inhibitors, Mrinalini Dey, a rheumatologist focusing on methotrexate side effects, and Chris Wincup, who dives into neuropsychiatric lupus. They reveal fascinating insights into JAK inhibitors, their safety, and the importance of vaccinations. Dey shifts perspectives on methotrexate side effects, while she and Wincup emphasize recognizing neuropsychiatric symptoms in lupus, advocating for improved communication and awareness in patient care.

Discover the long-term benefits of bimekizumab for psoriatic arthritis, showcasing improved patient quality of life. Unpack the revolutionary CAR-T therapy's potential for lupus treatment, along with personal patient insights. Dive into gender differences impacting treatment responses in ankylosing spondylitis and the metabolic factors linked to rheumatoid arthritis. Learn about cutting-edge ultrasound techniques enhancing psoriatic arthritis diagnoses and the promising effects of upadacitinib for giant cell arthritis management.